Ovid Therapeutics Inc.
OVID
$2.70
-$0.05-1.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -88.31% | -- | 844.74% | -23.70% | 3,611.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.31% | -- | 844.74% | -23.70% | 3,611.24% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -88.31% | -- | 844.74% | -23.70% | 3,611.24% |
| SG&A Expenses | 26.52% | 22.95% | 108.85% | 22.38% | -39.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.19% | 47.73% | 44.60% | -5.55% | -45.16% |
| Operating Income | -203.53% | -49.34% | -37.78% | 5.32% | 75.27% |
| Income Before Tax | -220.43% | -65.98% | 204.43% | 13.19% | -154.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -220.43% | -65.98% | 204.43% | 13.19% | -154.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.43% | -65.98% | 204.43% | 13.19% | -154.97% |
| EBIT | -203.53% | -49.34% | -37.78% | 5.32% | 75.27% |
| EBITDA | -209.25% | -50.83% | -40.10% | 4.21% | 75.58% |
| EPS Basic | -17.47% | 11.86% | 198.14% | 13.33% | -154.78% |
| Normalized Basic EPS | -13.11% | 22.47% | -80.54% | 13.79% | -161.95% |
| EPS Diluted | -17.47% | 11.86% | 198.14% | 13.33% | -154.78% |
| Normalized Diluted EPS | -13.11% | 22.47% | -80.54% | 13.79% | -162.14% |
| Average Basic Shares Outstanding | 177.67% | 91.67% | 15.01% | 0.19% | 0.27% |
| Average Diluted Shares Outstanding | 177.67% | 91.67% | 15.01% | 0.19% | -0.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |